Unlike the US drug regulator, however, the Indian drug regulator, CDSCO, does not yet require the pharma industry to control for nitrosamines. This means that firms that supply to the Indian market are currently left to their own devices
from mint - Science https://ift.tt/3jX9z1J
https://ift.tt/eA8V8J
from mint - Science https://ift.tt/3jX9z1J
https://ift.tt/eA8V8J
إرسال تعليق